Truist upgraded Globus Medical (GMED) to Buy from Hold with a price target of $93, up from $65. The firm has greater confidence in the company’s mid- to high-single-digit revenue growth outlook with low- to mid-teens earnings growth. Nevro accretion is getting pulled forward nearly one year ahead of expectations while Globus is seeing accelerating trends in the core spine business, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: